218 related articles for article (PubMed ID: 31779864)
1. Therapeutic experience of ticagrelor in Indian patients with acute coronary syndrome: A non-interventional, prospective, and observational study.
Sawhney JPS; Dalal J; Mullasari A; Bansal S; Kahali D
Indian Heart J; 2019; 71(4):344-349. PubMed ID: 31779864
[TBL] [Abstract][Full Text] [Related]
2. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
[TBL] [Abstract][Full Text] [Related]
3. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
4. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Turgeon RD; Koshman SL; Youngson E; Har B; Wilton SB; James MT; Graham MM
JAMA Intern Med; 2020 Mar; 180(3):420-428. PubMed ID: 31930361
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor: a review of its use in adults with acute coronary syndromes.
Dhillon S
Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
[TBL] [Abstract][Full Text] [Related]
6. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.
Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G;
JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605
[TBL] [Abstract][Full Text] [Related]
7. Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.
D'Ascenzo F; Biolè C; Raposeiras-Roubin S; Gaido F; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Templin C; Wilton SB; Omedè P; Velicki L; Xanthopoulou I; Correia L; Cerrato E; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Song X; Gili S; Magnani G; Autelli M; Bongiovanni F; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Alexopoulos D; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; Pousa IM; Kawashiri MA; Rettegno S; Gallo D; Morbiducci U; Conrotto F; Dominguez-Rodriguez A; Valdés M; Cequier A; Iñiguez-Romo A; Biondi-Zoccai G; Stone GW; De Ferrari GM
Am Heart J; 2020 Feb; 220():108-115. PubMed ID: 31809991
[TBL] [Abstract][Full Text] [Related]
8. Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor.
Verdoia M; Nardin M; Gioscia R; Negro F; Marcolongo M; Suryapranata H; Kedhi E; De Luca G;
Vascul Pharmacol; 2020 Sep; 132():106765. PubMed ID: 32681888
[TBL] [Abstract][Full Text] [Related]
9. Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry.
De Filippo O; Cortese M; D Ascenzo F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Montefusco A; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Rinaldi M
Am J Cardiovasc Drugs; 2019 Aug; 19(4):381-391. PubMed ID: 31030413
[TBL] [Abstract][Full Text] [Related]
10. Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine.
Lapostolle F; Van't Hof AW; Hamm CW; Stibbe O; Ecollan P; Collet JP; Silvain J; Lassen JF; Heutz WMJM; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Goodman SG; Hammett CJ; Huber K; Janzon M; Merkely B; Storey RF; Ten Berg J; Zeymer U; Licour M; Tsatsaris A; Montalescot G;
Am J Cardiovasc Drugs; 2019 Apr; 19(2):173-183. PubMed ID: 30353444
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
[TBL] [Abstract][Full Text] [Related]
12. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.
Baber U; Dangas G; Angiolillo DJ; Cohen DJ; Sharma SK; Nicolas J; Briguori C; Cha JY; Collier T; Dudek D; Džavik V; Escaned J; Gil R; Gurbel P; Hamm CW; Henry T; Huber K; Kastrati A; Kaul U; Kornowski R; Krucoff M; Kunadian V; Marx SO; Mehta S; Moliterno D; Ohman EM; Oldroyd K; Sardella G; Sartori S; Shlofmitz R; Steg PG; Weisz G; Witzenbichler B; Han YL; Pocock S; Gibson CM; Mehran R
Eur Heart J; 2020 Oct; 41(37):3533-3545. PubMed ID: 33085967
[TBL] [Abstract][Full Text] [Related]
13. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW
Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386
[TBL] [Abstract][Full Text] [Related]
14. Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study.
Yao Y; Wang P; Wang XZ; Zhao X; Zhao W; Zhou TN; Zhang L
Chin Med J (Engl); 2019 Oct; 132(19):2292-2299. PubMed ID: 31567375
[TBL] [Abstract][Full Text] [Related]
15. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
16. Safety of Preoperative Use of Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Grafting.
Gherli R; Mariscalco G; Dalén M; Onorati F; Perrotti A; Chocron S; Verhoye JP; Gulbins H; Reichart D; Svenarud P; Faggian G; Santarpino G; Fischlein T; Maselli D; Dominici C; Musumeci F; Rubino AS; Mignosa C; De Feo M; Bancone C; Gatti G; Maschietto L; Santini F; Nicolini F; Gherli T; Zanobini M; Kinnunen EM; Ruggieri VG; Rosato S; Biancari F
JAMA Cardiol; 2016 Nov; 1(8):921-928. PubMed ID: 27653165
[TBL] [Abstract][Full Text] [Related]
17. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A
BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837
[TBL] [Abstract][Full Text] [Related]
18. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
19. YINGLONG: A Multicenter, Prospective, Non-Interventional Study Evaluating the Safety and Tolerability of Ticagrelor in Chinese Patients with Acute Coronary Syndrome.
Du X; Zheng Y; Yang P; Ma S; Yu Z; Su X; Ge J; Leonsson-Zachrisson M; Wang X; Sun J; Bai L; Ma CS;
Adv Ther; 2019 Jul; 36(7):1595-1605. PubMed ID: 31119693
[TBL] [Abstract][Full Text] [Related]
20. Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry.
Zeymer U; Cully M; Hochadel M
Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):205-210. PubMed ID: 29878086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]